Author(s)
Bess Dawson-Hughes, Susan S. Harris, Nancy J. Palermo, Carmen Castaneda-Sceppa, Helen M. Rasmussen, and Gerard E. Dallal
Treatment with Potassium Bicarbonate Lowers Calcium Excretion and Bone Resorption in Older Men and Women

Bess Dawson-Hughes, Susan S. Harris, Nancy J. Palermo, Carmen Castaneda-Sceppa, Helen M. Rasmussen, and Gerard E. Dallal

Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University (B.D.-H., S.S.H., N.J.P., H.M.R., G.E.D.), Boston, Massachusetts 02111; and Bouve College of Health Sciences (C.C.-S.), Northeastern University, Boston, Massachusetts 02115

Context: Bicarbonate has been implicated in bone health in older subjects on acid-producing diets in short-term studies.

Objective: The objective of this study was to determine the effects of potassium bicarbonate and its components on changes in bone resorption and calcium excretion over 3 months in older men and women.

Design, Participants, and Intervention: In this double-blind, controlled trial, 171 men and women age 50 and older were randomized to receive placebo or 67.5 mmol/d of potassium bicarbonate, sodium bicarbonate, or potassium chloride for 3 months. All subjects received calcium (600 mg of calcium as triphosphate) and 525 IU of vitamin D₃ daily.

Main Outcome Measures: Twenty-four-hour urinary N-telopeptide and calcium were measured at entry and after 3 months. Changes in these measures were compared across treatment groups in the 162 participants included in the analyses.

Results: Bicarbonate affected the study outcomes, whereas potassium did not; the two bicarbonate groups and the two no bicarbonate groups were therefore combined. Subjects taking bicarbonate had significant reductions in urinary N-telopeptide and calcium excretion, when compared with subjects taking no bicarbonate (both before and after adjustment for baseline laboratory value, sex, and changes in urinary sodium and potassium; \( P = 0.001 \) for both, adjusted). Potassium supplementation did not significantly affect N-telopeptide or calcium excretion.

Conclusions: Bicarbonate, but not potassium, had a favorable effect on bone resorption and calcium excretion. This suggests that increasing the alkali content of the diet may attenuate bone loss in healthy older adults. (J Clin Endocrinol Metab 94: 96–102, 2009)

Hereditary, diet, and other lifestyle factors contribute to the problem of bone loss and fractures. Of the dietary constituents affecting bone, calcium and vitamin D have received the most attention, but there is increasing evidence that the acid/base balance of the diet is also important. Fruits and vegetables are metabolized to bicarbonate and are thus alkali-producing, whereas protein and cereal grains are metabolized to acid and thus are acid-producing or acidogenic. On average, American diets tend to be acidogenic, producing an excess of about 75 mEq of acid per day (1). With aging there is a decline in renal function (2, 3), a decreased capacity to excrete hydrogen ions, and a gradually increasing metabolic acidosis. In a comprehensive review, Frassetto and Sebastian (4) identified a 6 to 7% rise in blood \([H^+]\) and a 12 to 16% decline in plasma \([HCO_3^-]\) between ages 20 and 80 yr, with most of the change occurring after age 50.

Abbreviations: ANCOVA, Analysis of covariance; BMD, bone mineral density; Cr, creatinine; CV, coefficient of variation; NAE, net acid excretion; NTX, N-telopeptide.
An acidic environment affects bone in several ways. It inhibits osteoblastic activity (5–9), increases osteoclastic activity (10, 11), and may also increase bone resorption by a direct, noncellular physicochemical process (12). Acidogenic (high-protein) diets induce calciuria (13–16), and administration of alkaline salts of potassium for 7 to 18 d to healthy subjects on controlled high protein diets lowers biochemical markers of bone turnover and reduces calcium excretion (17, 18). If sustained, these changes should have a favorable effect on calcium balance and bone mass.

There is no consensus on the individual contributions of the anion and cation to the favorable effects of potassium bicarbonate on indices of bone metabolism. Several investigators have concluded that the potassium impacts calcium balance, largely on the basis that it decreases calcium excretion (19, 20). Moreover, higher potassium intakes, as seen in diets rich in fruits and vegetables, have been associated with higher femoral neck bone mineral density (BMD) and lower biochemical markers of bone turnover in adult women (21). In contrast, others have implicated the bicarbonate, which consistently lowers calcium excretion (18, 22, 23) and has also reduced biochemical markers of bone resorption (23, 24).

This study was conducted to determine the impact of 3 months of treatment with KHCO₃ and its components, potassium and HCO₃⁻, on biochemical markers of bone turnover and calcium excretion.

### Subjects and Methods

#### Subjects

Healthy ambulatory men and women age 50 and older were recruited through direct mailings and advertisements in the community. The women were menopausal for at least 6 months. The criteria for exclusion included: vegetarianism, adrenal insufficiency, diabetes mellitus (fasting sugar >130 mg/dl), alcohol use exceeding 2 U/d, peptic ulcers or esophageal stricture, active malignancy, untreated thyroid disease, significant immune disorder, uncontrolled hypertension (>140/90 mm Hg), congestive heart failure, arrhythmias, myocardial infarction in the last 12 months, salt-restricted diets, gastroesophageal reflux disease requiring treatment with sodium- or alkali-containing antacids, kidney stones in the last 5 yr, creatinine (Cr) clearance less than 50 ml/min/1.73 m², 24-h urine calcium greater than 300 mg/d after 1 wk off of calcium supplements, total hip T-score less than −2.5, 24-h hydroxyvitamin D level below 16 ng/ml, use of gonadal hormones or other medications for osteoporosis in the last 2 yr, creatinine clearance less than 30 ml/min/1.73 m², and reduced calcium excretion (23, 24).

The active treatments were given in amounts of 67.5 mmol/d, in nine gelatin capsules (containing 7.5 mmol each), and the placebo capsules contained an equal volume of microcrystalline cellulose. Subjects were asked to take one capsule three times daily during wk 1, two capsules three times daily during wk 2, and three capsules three times daily thereafter. All capsules were taken with an 8-oz glass of water immediately after meals. The capsules were made by a local compounding pharmacy (The Medical Pharmacy and Supply, Stoughton, MA).

#### Analytic methods

Blood was drawn between 0700 and 0930 h after the subjects had fasted for 12 h. All samples from individual subjects except the safety blood on d 21 were batched for analyses. The 24-h urine measures are presented as Cr ratios, to correct for variation in the completeness of the urine collections. Serum 25-hydroxyvitamin D was measured with RIA kits from Diasorin (Stillwater, MN) with a coefficient of variation (CV) of 5.6 to 7.7%. Serum intact PTH and osteocalcin were measured by chemiluminescent immunoradiometric assays on an automated immunoassay system (IMMULITE 1000, Diagnostic Product Corp., Los Angeles, CA), with CVs of 3 to 9%. Serum calcium, potassium, and Cr and urinary potassium and sodium were measured on an automated clinical chemistry analyzer (Olympus AU400, Olympus America Inc., Melville, NY) with CVs of 3.0 to 6.0%. Twenty-four-hour urinary calcium was measured by direct-current plasma emission spectroscopy (Beckman SpectraSpan VI Direct Current Plasma Emission Spectrophotometer; Beckman Instruments, Fullerton, CA) with a CV of 3–5%. Urinary N-telopeptide (NTX) was measured by ELISA (Wampole, Princeton, NJ) with a CV of 5.6 to 7.7%. Urinary nitrogen was measured with a model FP-2000 nitrogen/protein determinator (LECO, St. Joseph, MI). This instrument employs a Dumas combustion method and detection using a thermal conductivity cell; it measures nitrogen with a precision of 15 ppm.

Net acid excretion (NAE) was measured in 24-h urine collections by a modification of the Jorgensen titration method (27), as described by Chan (28). NAE equals titratable acid plus NH₄⁺ minus HCO₃⁻. Briefly, titratable acid minus HCO₃⁻ was assessed after adding HCl, boiling the sample, and then titrating the sample to neutral pH. To measure the NH₄⁺, formol was added to the sample to release the H⁺ from NH₄⁺.
and the sample was again titrated to neutral pH. All titrations were carried out with a TIM 900 Titration Manager (Radiometer Analytical, Loveland, CO). The precision of NAE measurements in our laboratory was determined by analyzing aliquots of a single 24-h urine collection on 15 different days. The aliquots were stored frozen at −80°C and thawed only once. The CV of the NAE measurements was 10.1%.

BMD of the total hip was measured on the screening visit with a GE Lunar model Prodigy scanner (Madison, WI). The precision of NAE measurements in our laboratory was determined by analyzing aliquots of a single 24-h urine collection on 15 different days. The aliquots were stored frozen at −80°C and thawed only once. The CV of the NAE measurements was 10.1%.

### Statistical analyses

The primary endpoints in this analysis were the 3-month changes in the 24-h NTX/Cr ratio (ΔNTX/Cr), urinary calcium/Cr ratio (ΔCa/Cr), and 3-month change in serum osteocalcin. Changes in other laboratory values were investigated in a similar manner. We examined changes in the endpoints by analysis of covariance and evaluated a limited set of post hoc comparisons (KHCO₃ vs. NaHCO₃, KCl vs. placebo, and KHCO₃ vs. KCl) by the least significant differences method. We did not stratify by sex because we found no significant interactions of sex with HCO₃ on the endpoints, but we did adjust for sex in all analyses. T-tests were used to compare baseline characteristics across HCO₃ groups. SPSS version 15.0 (SPSS Inc., Chicago, IL) was used for all statistical analyses, and P values <0.05 were considered to indicate statistical significance.

### Status of subjects and adherence

Of the 171 enrolled, seven subjects (4%) dropped out of the study (placebo group, one with cardiac event; NaHCO₃, one with high blood pressure, one with headaches, and two lost interest; KCl, one with prostate cancer; KHCO₃, one lost interest). In addition, one subject in the KHCO₃ group was excluded from the analyses because he was believed to have a metabolic bone disease, possibly renal tubular acidosis, on the basis of high baseline NAE, NTX, and calcium excretion values. One other subject was excluded because of high baseline NTX excretion.

### Results

#### Selection of analysis groups

The four treatments were selected to allow us to address the question of whether the potassium, the bicarbonate, or both are important to achieve effects on calcium excretion and bone resorption. The four groups did not differ significantly in age, body weight, sex distribution, dietary intake of calcium or vitamin D, or in baseline levels of urinary NTX/Cr, serum osteocalcin, or calcium/Cr excretion (data not shown). As expected, the 3-month change in sodium/Cr excretion was higher in the NaHCO₃ group than in the other groups [analysis of covariance (ANCOVA) \( P = 0.003 \), after adjustment for sex and baseline sodium/Cr excretion]. Three-month change in mean urinary NTX/Cr differed significantly among the four groups (ANCOVA \( P = 0.024 \), after adjustment for sex and baseline NTX/Cr). As shown in Fig. 1, NTX/Cr declined in the two bicarbonate groups but not in the two groups without bicarbonate. The change differed significantly between the KCl and the KHCO₃ groups (\( P = 0.015 \)), but not between the two bicarbonate groups (\( P = 0.243 \)) or between groups not taking bicarbonate, the placebo and KCl group (\( P = 0.773 \)). The patterns of change in the four groups were similar for serum osteocalcin and urine calcium/Cr. Therefore, for subsequent analyses, we combined the two HCO₃ groups and the groups with no HCO₃ and focused on the effect of HCO₃ treatment on the endpoints, adjusting for \( \Delta K/Cr, \Delta Na/Cr, \text{sex, and baseline value of the endpoint} \).

#### Main results

The clinical characteristics of the 162 subjects by HCO₃ group are shown in Table 1. There were no significant group differences in any of these baseline characteristics. During the study, weight did not change significantly in either group (0.18 ± 1.96 kg, \( P = 0.422 \)).

### Table 1. Baseline characteristics (mean ± sd) of the 162 study subjects by treatment group

<table>
<thead>
<tr>
<th></th>
<th>No HCO₃</th>
<th>HCO₃</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>84</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>63.3 ± 7.7</td>
<td>62.4 ± 7.6</td>
<td>0.453</td>
</tr>
<tr>
<td>Female (%)</td>
<td>59.3</td>
<td>55.1</td>
<td>0.681</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>167.0 ± 6.8</td>
<td>168.6 ± 9.9</td>
<td>0.293</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>72.2 ± 13.6</td>
<td>74.9 ± 13.7</td>
<td>0.207</td>
</tr>
<tr>
<td>Dietary calcium intake (mg/d)</td>
<td>772 ± 386 (83)</td>
<td>880 ± 431</td>
<td>0.095</td>
</tr>
<tr>
<td>Dietary vitamin D (IU/d)</td>
<td>206 ± 144 (83)</td>
<td>247 ± 135</td>
<td>0.066</td>
</tr>
<tr>
<td>Physical activity score</td>
<td>168 ± 84 (81)</td>
<td>156 ± 82 (75)</td>
<td>0.366</td>
</tr>
</tbody>
</table>

Numbers in parentheses indicate sample size.
in the HCO₃ group; and −0.04 ± 1.50, *P* = 0.803 kg in the no HCO₃ group). Mean adherence in the 153 subjects with adequate adherence data was 94.6 ± 12.5% in the HCO₃ group and 86.5 ± 22.8% in the no HCO₃ group; among the 143 subjects who were taking any pills at the end of the study, mean adherence was 96.3 ± 6.2% and 91.4 ± 14.8%, respectively.

The baseline biochemical measurements and changes over the 3-month study in the HCO₃ and no HCO₃ groups (after adjustment for sex, baseline value, and changes in sodium/Cr and K/Cr excretion, except when they were the dependent variables) are shown in Table 2. There were no statistically significant group differences in any of these measures at baseline except NAE/Cr, which was higher in the HCO₃ group. As expected, ΔNAE/Cr differed significantly in the two groups (*P* < 0.001). Subjects supplemented with HCO₃ for 3 months had significantly greater adjusted mean changes in calcium/Cr excretion (*P* = 0.002) and urinary NTX/Cr (*P* = 0.002) than subjects in the no HCO₃ group. These changes are illustrated in Fig. 2.

In ANCOVA, NAE/Cr on d 84 was significantly associated with calcium excretion on d 84 (β = 0.61, *P* < 0.001, after adjustment for sex, baseline calcium/Cr excretion, and for sodium/Cr and K/Cr excretion on d 84). Similarly, NAE/Cr on d 84 was significantly associated with NTX/Cr on d 84 (β = 0.18, *P* < 0.001, after adjustment for sex, baseline urinary NTX/Cr, and sodium/Cr and K/Cr excretion on d 84). To illustrate these associations, Fig. 3 displays the adjusted mean 24-h urine calcium/Cr and NTX/Cr values by tertile of NAE/Cr on d 84 in the 162 subjects.

Serum potassium concentration was determined in each subject after 3 wk in the study as a safety measure. Three subjects treated with potassium had serum potassium levels over 5 mg/dl, the upper end of the reference range, and their values were 5.1, 5.1, and 5.2 mg/dl; five subjects not treated with potassium had serum potassium levels over 5 mg/dl, and their values were 5.1, 5.2, 5.2, 5.3, and 5.4 mg/dl. Blood pressure did not exceed 145/90 mm Hg at entry in any subject. One subject in the NaHCO₃ group had blood pressure exceed 145/95 mm Hg during the trial; she was unavailable for a repeat blood pressure check and so was asked to discontinue the study pills. The supplements were generally well tolerated, but 12 discontinued treatment because of gastrointestinal

---

### TABLE 2. Mean ± SEM baseline and 3-month changes in laboratory values by bicarbonate treatment status

<table>
<thead>
<tr>
<th></th>
<th><strong>No HCO₃</strong> (n = 84)</th>
<th><strong>HCO₃</strong> (n = 78)</th>
<th><strong>P</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Serum</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium (mg/dl)</td>
<td>9.38 ± 0.04</td>
<td>9.27 ± 0.04</td>
<td>0.063</td>
</tr>
<tr>
<td>Change</td>
<td>−0.02 ± 0.04</td>
<td>0.07 ± 0.04</td>
<td>0.112</td>
</tr>
<tr>
<td>Phosphorus (mg/dl)</td>
<td>3.39 ± 0.05</td>
<td>3.43 ± 0.06</td>
<td>0.653</td>
</tr>
<tr>
<td>Change</td>
<td>0.10 ± 0.04</td>
<td>0.01 ± 0.04</td>
<td>0.129</td>
</tr>
<tr>
<td>PTH (pg/ml)</td>
<td>53.5 ± 1.93</td>
<td>57.9 ± 2.3</td>
<td>0.141</td>
</tr>
<tr>
<td>Baseline</td>
<td>−1.5 ± 1.6</td>
<td>−2.0 ± 1.9</td>
<td>0.807</td>
</tr>
<tr>
<td>Change</td>
<td>0.07 ± 0.04*a</td>
<td>0.001 ± 0.037</td>
<td>0.200</td>
</tr>
<tr>
<td>Potassium (mEq/liter)</td>
<td>4.49 ± 0.04</td>
<td>4.39 ± 0.04</td>
<td>0.080</td>
</tr>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteocalcin (ng/ml)</td>
<td>7.36 ± 0.41</td>
<td>7.44 ± 0.49</td>
<td>0.906</td>
</tr>
<tr>
<td>Baseline</td>
<td>0.36 ± 0.21</td>
<td>−0.17 ± 0.22</td>
<td>0.077</td>
</tr>
<tr>
<td>Change</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urine</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium/Cr (mg/g)</td>
<td>114.04 ± 7.05</td>
<td>125.30 ± 7.36</td>
<td>0.271</td>
</tr>
<tr>
<td>Baseline</td>
<td>18.34 ± 5.00</td>
<td>−5.38 ± 5.16</td>
<td>0.001</td>
</tr>
<tr>
<td>Change</td>
<td>57.94 ± 2.38</td>
<td>58.82 ± 2.61</td>
<td>0.802</td>
</tr>
<tr>
<td>Potassium/Cr (mEq/g)</td>
<td>12.49 ± 3.20</td>
<td>14.95 ± 3.32</td>
<td>0.979</td>
</tr>
<tr>
<td>Baseline</td>
<td>111.49 ± 4.79</td>
<td>105.18 ± 4.34</td>
<td>0.333</td>
</tr>
<tr>
<td>Change</td>
<td>5.98 ± 4.31</td>
<td>18.15 ± 4.48</td>
<td>0.053</td>
</tr>
<tr>
<td>Sodium/Cr (mEq/g)</td>
<td>38.07 ± 1.84</td>
<td>38.19 ± 1.92</td>
<td>0.964</td>
</tr>
<tr>
<td>Baseline</td>
<td>0.44 ± 1.19</td>
<td>−5.11 ± 1.23</td>
<td>0.001</td>
</tr>
<tr>
<td>NTX/Cr (nmol/mmol)</td>
<td>24.6 ± 1.7</td>
<td>31.0 ± 2.5</td>
<td>0.034</td>
</tr>
<tr>
<td>Baseline</td>
<td>3.6 ± 1.8</td>
<td>−35.2 ± 3.3</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Changes are adjusted for sex, baseline laboratory value, and (except when it is the dependent variable) for the change in urinary sodium to Cr and the change in urinary potassium to Cr.

*a* One subject with missing value.
tinal symptoms (placebo, one subject; KHCO₃, one; NaHCO₃, three; and KCl, seven), and four discontinued pills for reasons unrelated to the pills.

**Discussion**

Supplementation with 67.5 mmol/d of bicarbonate for 3 months had the favorable effects of decreasing calcium excretion and lowering the biochemical marker of bone resorption, NTX. Subjects in the HCO₃ group had a relative decrease in calcium excretion compared with subjects in the no HCO₃ group. All subjects took a calcium supplement daily throughout the study, which probably accounts for the increase in calcium excretion seen in the no HCO₃ group and may have reduced the treatment-related decrease in the HCO₃ group. In this study, we chose to use a neutral calcium supplement, calcium triphosphate; use of an alkali-producing supplement such as calcium carbonate or calcium citrate would have neutralized some of the acid load in these subjects. Our finding is consistent with the short-term studies that have reported that alkaline salts of potassium administered over a period of up to 3 wk lower 24-h calcium excretion (17, 18), and it extends these observations to demonstrate that the effect is present after 3 months. A recent report indicated that treatment of postmenopausal women with 33.5 mmol/d of potassium citrate (compared with potassium chloride) decreased excretion of the bone resorption markers, pyridinoline and deoxypyridinoline, after 3 months but not after 1 yr; despite this, however, the intervention lowered rates of bone loss from the spine and hip (30). In contrast, MacDonald et al. (34) reported a significant effect of treatment with 55 mmol/d of KHCO₃ (vs. true placebo) on one biochemical marker of bone resorption at 4 to 6 wk (2-h fasting urinary free deoxypyridinoline crosslinks/Cr), but no effect on BMD at the spine or hip over a 2-yr period. Treatment with HCO₃ had no significant effect on serum osteocalcin in our study, in agreement with some (30, 34) but not with others who have noted modest increases in serum osteocalcin after 14 and 18 d of HCO₃ treatment (17, 35). The reason for the divergent findings is not apparent at this time.

Treatment with HCO₃ had no significant effect on serum PTH levels in this study. This finding is in agreement with other metabolic studies in normal subjects in which administration of oral acid and alkaline loads has not been found to alter PTH secretion over 1- to 2-wk periods (18, 24, 36, 37).

The NEA measurements in this study were valuable because they gave a quantitative estimate of the combined influences of net acid- or base-producing content of the subjects' self-selected diets and of their intervention (including compliance with the pills) on these outcomes. This integrated estimate allowed us to identify significant linear relationships between change in NAE and changes in NTX and calcium excretion, confirming that it is the reduction in acid load that was the active component of the treatment.

Like many others in the United States, our study population generally consumed acid-producing diets, as indicated by their positive mean NAE at entry into the study. Treatment with 67.5 mmol/d of HCO₃ reduced the mean NAE to around 0, illustrating that, on average, this dose was adequate to neutralize the net acid load of their usual diets. Because of variation in self-selected diets and in treatments, however, there was wide variation in NAE among the subjects at the end of this study. In the group as a whole at the end of the study, those with the lowest levels of NAE had the lowest levels of calcium and NTX excretion. The linear relationship between NAE and excretion of calcium bicarbonate on rates of bone turnover and bone loss. It will also be of interest to determine whether a net neutral or alkali-

![FIG. 3. Mean urinary NTX/Cr and Ca/Cr by NAE/Cr tertile at the end of the study, adjusted for sex, baseline value, and for sodium/Cr and K/Cr at the end of the study.](image-url)
ducing diet, achieved through the combination of high fruit and vegetable and reduced cereal grain intake or by coadministration of alkali, will influence the effect of dietary protein on the skeleton. Achieving alkali-producing diets would require drastic changes in food choices and be challenging in older people who tend to have long-established dietary patterns. Should it be shown to be beneficial, an alternative approach may be to administer bicarbonate in supplement form or to lower the acid-producing capacity of selected foods through alkali fortification.

Supplementation with potassium did not significantly alter calcium excretion or markers of bone turnover in this study. This is in contrast to earlier reports of Lemann et al. who found that increasing potassium intake decreased urinary calcium excretion. The apparently conflicting observation that higher potassium intake is associated with higher BMD in healthy perimenopausal women may result from the fact that potassium-rich diets tend to be alkali-producing, in that they are rich in fruits and vegetables. Treatment with potassium did enhance sodium excretion, as has been documented widely.

In conclusion, we have found that reducing the acidogenicity of the diet into the alkali-producing range with bicarbonate lowers calcium excretion and the bone resorption rate in healthy older men and women consuming typical acid-producing American diets. Treatment with 67.5 mmol/d of potassium bicarbonate was safe and well tolerated in this population. Increasing intake of alkali merits further consideration as a safe and low-cost approach to improving skeletal health in older men and women.

Acknowledgments

We express our appreciation to Dr. Catherine Gordon of Children’s Hospital in Boston for serving as the Safety Monitor of this study and to the staff of the Metabolic Research Unit, the Nutrition Evaluation Laboratory, and to the study participants for their valuable contributions to this study.

Address all correspondence to: Bess Dawson-Hughes, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111. E-mail: Bess.Dawson-Hughes@Tufts.edu.

Reprints will not be available.

Disclosure Statement: The authors have nothing to disclose.

References

31. Elders PJ, Netelenbos JC, Lips P, van Ginkel FC, Kloe E, Leeuwenkamp OR,


